.jpg)
1 hour ago
4
Article content
TORONTO, April 21, 2026 (GLOBE NEWSWIRE) — PharmAla Biotech Holdings Inc. (“PharmAla” or the “Company”) (CSE: MDMA) (OTC: MDXXF), a biotechnology company focused on the research, development, and manufacturing of LaNeo™ MDMA and novel derivatives of MDMA (MDXX class molecules), is pleased to have publicly filed its financial and operational results for the period ended February 28, 2026. All figures are reported in Canadian dollars. The Company’s full set of unaudited condensed interim consolidated financial statements for the quarter and accompanying management’s discussion and analysis can be accessed by visiting the Company’s website at www.PharmAla.ca and its profile page on SEDAR+ at www.sedarplus.ca.
THIS CONTENT IS RESERVED FOR SUBSCRIBERS ONLY
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman, and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
SUBSCRIBE TO UNLOCK MORE ARTICLES
Subscribe now to read the latest news in your city and across Canada.
- Exclusive articles from Barbara Shecter, Joe O'Connor, Gabriel Friedman and others.
- Daily content from Financial Times, the world's leading global business publication.
- Unlimited online access to read articles from Financial Post, National Post and 15 news sites across Canada with one account.
- National Post ePaper, an electronic replica of the print edition to view on any device, share and comment on.
- Daily puzzles, including the New York Times Crossword.
REGISTER / SIGN IN TO UNLOCK MORE ARTICLES
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account.
- Share your thoughts and join the conversation in the comments.
- Enjoy additional articles per month.
- Get email updates from your favourite authors.
THIS ARTICLE IS FREE TO READ REGISTER TO UNLOCK.
Create an account or sign in to continue with your reading experience.
- Access articles from across Canada with one account
- Share your thoughts and join the conversation in the comments
- Enjoy additional articles per month
- Get email updates from your favourite authors
Sign In or Create an Account
or
Article content
Article content
“PharmAla’s financial position continues to benefit from an operational focus by the Company’s management,” said Nick Kadysh, Founding CEO. “PharmAla continues to be the only Psychedelics company that has worked to understand and continually improve commercial implications, in Australia and beyond; As Psychedelics advance rapidly towards commercialization globally, this operational know-how will become only more valuable.”
Article content
Article content
By signing up you consent to receive the above newsletter from Postmedia Network Inc.
Article content
Financial Highlights:
Article content
- Customer deposits have continued to grow by $310,719 through Q2, offset by recognition of revenue of $181,492. These deposits, generally being 50% of the total contract value, can be recognized along with the remaining revenue when the related product is shipped, which for many customers requires the issuance of their clinical trial and/or import permits from relevant regulatory bodies.
- Revenues for the three and six months ended February 28, 2026 were $220,584 and $487,024 compared to $145,657 and $202,954 for the three and six months ended February 28, 2025.
- Net loss and comprehensive loss for the three and six months ended February 28, 2026 were $337,696 and $747,391 compared to $810,766 and $1,289,875 for the three and six months ended February 28, 2025.
- Cash used in operating activities was $366,396 for the six months ended February 28, 2026 compared to $491,721 for the six months ended February 28, 2025.
Article content
Article content
“Through Q2 2026, we have continued to see increased demand for our product, culminating in a steady increase in customer deposits,” said Will Avery, CFO, PharmAla Biotech. “With our proven supply chain in the U.S. and Australia we have been able to convert customer deposits into revenue at an improved rate.”
Article content
Issuance of Options:
PharmAla has issued options to the following Board Members and Officers. The options are issued subject to a vesting period, such that every 3 months 25% of the allotment will be vested, such that the options shall be fully vested on the 12 month anniversary of the date of grant, which is April 20, 2026. The options have a fixed exercise price per share of $0.10 (subject to adjustment in accordance with the terms of the Plan and/or stock option agreement). All vested but unexercised options shall expire and cease to be of effect on April 20, 2031.
Article content
| Name of Optionee | Position | Number of Options |
| Jodi Butts | Director | 350,000 |
| Kevin Roy | Director | 250,000 |
| Fraser Macdonald | Director | 250,000 |
| Perry Tsergas | Director | 250,000 |
| Lennie Ryer | Director | 250,000 |
| Nicholas Kadysh | Chief Executive Officer | 1,000,000 |
| Will Avery | Chief Financial Officer | 1,000,000 |
| Farnoud Kazemzadeh | Chief Operating Officer | 1,000,000 |
| Harpreet Kaur | Employee | 500,000 |
| Total | 4,850,000 | |
English (US)